SCHEMBL14930299

SCHEMBL14930299

CCN[C@@H]1CCCc2ccccc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.56
MAOA P21397 2/20 0.55
MAOB P27338 2/20 0.55
BCHE P06276 1/20 0.55
ADRA2B P18089 1/20 0.55
ADRA2C P18825 1/20 0.55
ACHE P22303 1/20 0.55
ADRA1A P35348 1/20 0.55
HTR6 P50406 1/20 0.55
KDM4E B2RXH2 3/20 0.54
ALDH1A1 P00352 3/20 0.54
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.52
PRMT5 O14744 1/20 0.52
TP53 P04637 1/20 0.52
CYP1A2 P05177 1/20 0.52
ADRB2 P07550 1/20 0.52
ADRB1 P08588 1/20 0.52
CYP3A4 P08684 1/20 0.52
ADRB3 P13945 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1327511 1.00 HTT (0.56) HTTMAOAMAOBBCHEADRA2B
SCHEMBL1327514 1.00 HTT (0.56) HTTMAOAMAOBBCHEADRA2B
SCHEMBL6851796 0.89 MAOA (0.68) HTTMAOAMAOBBCHEADRA2B
SCHEMBL6851081 0.89 MAOA (0.68) HTTMAOAMAOBBCHEADRA2B
SCHEMBL10282640 0.89 MAOA (0.68) HTTMAOAMAOBBCHEADRA2B
SCHEMBL62692 0.87 HTT (0.64) HTTMAOAMAOBBCHEADRA2B
SCHEMBL62691 0.87 HTT (0.64) HTTMAOAMAOBBCHEADRA2B
SCHEMBL19289840 0.87 HTT (0.64) HTTMAOAMAOBBCHEADRA2B
SCHEMBL8517647 0.83 HTT (0.56) HTTMAOAMAOBBCHEADRA2B
SCHEMBL8249322 0.83 ALDH1A1 (0.57) HTTMAOAMAOBBCHEADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2861581-B1 1,2,3,4-Tetrahydroisoquinoline-pyrrolidine derivatives as antagonists of apoptosis (IAPs) for the treatment of cancer. BRISTOL MYERS SQUIBB CO (US) 2017-02-01 EP disclosed
US-20130116227-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116227-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF MC2R, NR3C2, REN HTT 4193/4885MAOA 1420/4885MAOB 1077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.